Rubius announces 3 new patents
for cellular-therapy program

DR. PABLO J. CAGNONI is CEO of Rubius Therapeutics. The cellular-medicine manufacturer, which is building a new facility in Smithfield, has announced the issuance of three new U.S. patents. / COURTESY RUBIUS THERAPEUTICS
PROVIDENCE – Rubius Therapeutics, a Cambridge, Mass.-based biotech firm that develops and genetically engineers red blood cells for use in medications for rare diseases, cancer and autoimmune disorders, has been issued three new U.S. patents. Two of the issued patents are related to the matter and methods of use for an investigational cellular therapy for…

Want More Free?

To access 2 more articles, please log in or register for free.

Registered users get access to a limited number of free articles every month.

Register Now

Already registered? Login to access more free articles.

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -